Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice
- PMID: 36997210
- PMCID: PMC10049595
- DOI: 10.3399/bjgp23X732321
Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice
Conflict of interest statement
All authors are involved in Heidi J Siddle’s HEE/NIHR Senior Clinical Lectureship (reference: ICA-SCL-2018-04-ST2-004), which includes the IDEAs in Primary Care study (feasibility of primary care testing of anti-CCP for early detection of RA). Paul Emery and Kulveer Mankia lead an extensive programme of research focused on the identification, monitoring, and management of people at risk of RA. The Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: ExIST (BioMed Central Ltd, reference: ISRCTN53678960) is funded by Eli Lilly (US).
Comment in
-
Early identification of rheumatoid arthritis.Br J Gen Pract. 2023 Apr 27;73(730):202. doi: 10.3399/bjgp23X732609. Print 2023 May. Br J Gen Pract. 2023. PMID: 37105751 Free PMC article. No abstract available.
References
-
- Versus Arthritis. The state of musculoskeletal health 2021: arthritis and other musculoskeletal conditions in numbers. 2021 https://www.versusarthritis.org/media/24653/state-of-msk-health2-2021.pdf (accessed 8 Mar 2023).
-
- Nam JL, Hunt L, Hensor EMA, Emery P. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms — a cohort study. Ann Rheum Dis. 2016;75(8):1452–1456. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical